<DOC>
	<DOCNO>NCT01203943</DOCNO>
	<brief_summary>The primary purpose study evaluate safety PK profile CC-930 idiopathic pulmonary fibrosis patient .</brief_summary>
	<brief_title>A Study Characterize Safety , PK Biological Activity CC-930 Idiopathic Pulmonary Fibrosis ( IPF )</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
	<mesh_term>Lung Diseases , Interstitial</mesh_term>
	<criteria>Males female nonchildbearing potential ≥50 year age ( time signing informed consent document ) document IPF Diagnosis IPF base current ATS/ERS guideline Usual interstitial pneumonia ( UIP ) pattern HRCT and/or UIP pattern histopathology ( ie surgical lung biopsy ) , Exclusion know cause interstitial lung disease ( environmental exposure , connective tissue disease drug toxicity ) , Or UIP pattern surgical lung biopsy require HRCT inconsistent UIP FVC : &lt; 50 % predict &gt; 90 % predict DLco : &lt; 25 % predict &gt; 90 % predict Saturated oxygen ( SpO2 ) &lt; 92 % ( room air [ sea level ] rest ) . SpO2 &lt; 88 % ( room air [ ≥ 5,000 foot sea level ( 1524 meter ] ) rest ) Use cytotoxic/immunosuppressive agent ( prednisone ≤ 12.5 mg/day equivalent ) include , limited , azathioprine , cyclophosphamide , methotrexate cyclosporine within 4 week screen Use cytokine modulators : Use biologic agent ( etanercept , adalimumab , efalizumab , infliximab , golimumab , certolizumab ) within 12 week five halflives screen , case rituximab , use within 24 week screen recovery CD 19positive B lymphocyte last dose rituximab 24 week prior screen Alefacept within 24 month randomization Use therapy target treat IPF ( include limit dpenicillamine , endothelium receptor antagonist [ eg bosentan , ambrisentan ] , interferon gamma1B , pirfenidone ) within 4 week screen Use nacetylcysteine ( NAC ) IPF ( ≥1800 mg/day ) within 4 week screen Use investigational drug within one month screening , 5 PD/PK half life , know ( whichever longer ) Current smoker</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Idiopathic Pulmonary Fibrosis</keyword>
	<keyword>Pulmonary Fibrosis</keyword>
	<keyword>Fibrosis</keyword>
	<keyword>Interstitial Lung Disease</keyword>
	<keyword>Lung Diseases , Interstitial</keyword>
	<keyword>CC-930</keyword>
</DOC>